An immunohistochemical and fluorescence in situ hybridization-based comparison between the oracle HER2 bond immunohistochemical system, Dako HercepTest, and Vysis PathVysion HER2 FISH using both commercially validated and modified ASCO/CAP and United Kingdom HER2 IHC scoring guidelines

Applied Immunohistochemistry and Molecular Morphology

Volumn 18, Issue 6, 2010, Pages 489-493

  O'Grady, Anthony ^a   Allen, David ^a   Happerfield, Lisa ^b   Johnson, Nicola ^b   Provenzano, Elena ^b   Pinder, Sarah E ^c   Tee, Lilian ^d   Gu, Mai ^d   Kay, Elaine W ^a  

^a BEAUMONT HOSPITAL   (Ireland)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d Oncotech Inc   (United States)

Author keywords

fluorescence in situ hybridization; HER2; immunohistochemistry; scoring guidelines

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ANALYTICAL EQUIPMENT; ARTICLE; AUTOMATION; BREAST CANCER; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PATHOLOGIST; PRACTICE GUIDELINE; PRIORITY JOURNAL; SCORING SYSTEM; STANDARDIZATION; VALIDATION PROCESS;

AUTOMATION; BREAST NEOPLASMS; FEMALE; GUIDELINES AS TOPIC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; PARAFFIN EMBEDDING; RECEPTOR, ERBB-2; RESEARCH DESIGN; SENSITIVITY AND SPECIFICITY; STAINING AND LABELING; TUMOR MARKERS, BIOLOGICAL;

EID: 78650510483     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e3181e3d893     Document Type: Article

References (24)

1. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177-182.
2. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/ neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707-712. (Pubitemid 19147683)
3. Pauletti G, Godolphin W, Press MF, et al. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene. 1996;13:63-72. (Pubitemid 26248546)
4. Walker RA, Bartlett J, Dowsett M, et al. HER2 testing in the UKfurther update to recommendations. J Clin Pathol. 2008; 61: 818-824. (Pubitemid 351969725)
5. Kell MR, Power CP. Adjuvant trastuzumab for breast cancer: assessing HER2/neu status incurs more costs for treatment. BMJ. 2005;331:1202.
6. van de Vijver M, Bilous M, Hanna W, et al. Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring study. Breast Cancer Res. 2007;9:R68.
7. Hanna WM, Kwok K. Chromogenic in-situ hybridization: a viable alternative to fluorescence in-situ hybridization in the HER2 testing algorithm. Mod Pathol. 2006;19:481-487.
8. Dietel M, Ellis IO, Hofler H, et al. Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American Pathologists. Virchows Arch. 2007;451:19-25.
9. Perez EA, Roche PC, Jenkins RB, et al. HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. Mayo Clin Proc. 2002;77:148-154.
10. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118-145. (Pubitemid 350003059)
11. Press MF, Hung G, Godolphin W, et al. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res. 1994;54:2771-2777. (Pubitemid 24173773)
12. Penault-Llorca F, Adelaide J, Houvenaeghel G, et al. Optimization of immunohistochemical detection of ERBB2 in human breast cancer: impact of fixation. J Pathol. 1994;173:65-75. (Pubitemid 24182263)
13. Gancberg D, Jarvinen T, di Leo A, et al. Evaluation of HER-2/NEU protein expression in breast cancer by immunohistochemistry: an interlaboratory study assessing the reproducibility of HER-2/NEU testing. Breast Cancer Res Treat. 2002; 74:113-120. (Pubitemid 34816216)
14. Rhodes A, Jasani B, Anderson E, et al. Evaluation of HER-2/neu immunohistochemical assay sensitivity and scoring on formalinfixed and paraffin-processed cell lines and breast tumors: a comparative study involving results from laboratories in 21 countries. Am J Clin Pathol. 2002;118:408-417. (Pubitemid 37046339)
15. Dowsett M, Bartlett J, Ellis IO, et al. Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. J Pathol. 2003;199:418-423. (Pubitemid 36411217)
16. Roche PC, Ingle JN. Increased HER2 with US food and drug administration-approved antibody. J Clin Oncol. 1999;17:434.
17. Maia DM. Immunohistochemical assays for HER2 overexpression. J Clin Oncol. 1999;17:1650.
18. Jacobs TW, Gown AM, Yaziji H, et al. Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States food and drug administration-approved scoring system. J Clin Oncol. 1999;17:1983-1987. (Pubitemid 29318825)
19. Clark GM. Should selection of adjuvant chemotherapy for patients with breast cancer be based on erbB-2 status? J Natl Cancer Inst. 1998;90:1320-1321.
20. Falo C, Moreno A, Lloveras B, et al. Algorithm for the diagnosis of HER-2/neu status in breast-infiltrating carcinomas. Am J Clin Oncol. 2003;26:465-470. (Pubitemid 37248262)
21. Tubbs RR, Pettay JD, Roche PC, et al. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol. 2001;19:2714-2721.
22. Bankfalvi A, Simon R, Brandt B, et al. Comparative methodological analysis of erbB-2/HER-2 gene dosage, chromosomal copy number and protein overexpression in breast carcinoma tissues for diagnostic use. Histopathology. 2000;37:411-419.
23. Sawaki M, Ito Y, Akiyama F, et al. High prevalence of HER-2/neu and p53 overexpression in inflammatory breast cancer. Breast Cancer. 2006;13:172-178.
24. Leong AS. Quantitation in immunohistology: fact or fiction? A discussion of variables that influence results. Appl Immunohistochem Mol Morphol. 2004;12:1-7.